In just the last 10 years, biopharmaceutical supply chains have changed dramatically. The single-source manufacturing model is becoming much rarer, making way for multi-enterprise manufacturing collaborations and partnerships to better meet the changing needs of the...
The days of maintaining paper records across the life sciences development and production pipeline are gone. Today’s regulatory requirements, not to mention the complexity of new treatments, requires organization that can only be provided electronically. However,...
There can be little question that Industry 4.0 technologies are reshaping the way life sciences companies operate. In the wake of the rapid development of vaccines during the COVID-19 pandemic, more facilities than ever are being “born digital.” Some of these...
The BioPhorum CGT Personas and User Stories toolkit details the needs of all the key players involved in end-to-end cell and gene therapy (CGT) processes. It can be used by anyone who wishes to better understand how IT systems can support the manufacture and delivery of CGTs.
For biotech industries, Emerson offers fundamental automation solutions with quicker uptimes and more consistent batch quality.
Reliability of assets used in the manufacturing process is paramount for safe, efficient and effective operations. Unplanned asset failures, improper asset performance, poor maintenance planning, and untimely follow-through can cause shutdowns, under-utilized production equipment, deviations, or material/product losses.
At the recent conference for pharmaceutical and biotech manufacturers, Interphex 2012, Pharmaceutical Manufacturing magazine Editor in Chief Agnes Shanley discussed trends in the industry's use of process analytical technology (PAT) and quality by design (QbD) with...
It was just about a year ago that the U.S. Food and Drug Administration published their Guidance for Industry - Process Validation: General Principles and Practices. I caught up with Emerson's Heather Schwalje, a senior consultant on the Life Sciences industry team....
An Emerson fellow blogger, Alan Babbitt, and his Emerson Global Life Sciences Blog was first to the scene to cover a great Bioprocess International article, Hurry Up and Wait? The article, by Emerson senior Life Sciences industry consultant, Michalle Adkins, describes...
I caught up the other day with Emerson's Shenling Yang, who is a senior project execution engineer in the Life Sciences and Food & Beverage (LSFB) industry group. You may recall Shenling from earlier posts. She shared two pieces of news with me. The first is that...
We invite you to follow us on Facebook, LinkedIn, Twitter and YouTube to keep up to date on all the latest news, events and innovations to help you take on and solve your toughest challenges.
Please do, Just link back to the post and send us a quick note so we can share your work. Thanks!
Our Global Community
Emerson Exchange 365
The opinions expressed here are the personal opinions of the authors. Content published here is not read or approved by Emerson before it is posted and does not necessarily represent the views and opinions of Emerson.